Contact:

John J. Quirk / Kim Sutton Golodetz / David K. Waldman	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

Quigley's Compound For Influenza Tests Positive in Preliminary in vitro SARS Virus Study

Professor John S. Oxford Presents Study Results to Quigley Scientific Advisory Board

DOYLESTOWN, PA. - December 8, 2003 - The Quigley Corporation (Nasdaq: QGLY) today announced that an independent in vitro study conducted by Retroscreen Virology Limited, found that a Quigley test compound previously tested on the Influenza virus showed "significant virucidal activity against the Urbani strain of the Severe Acute Respiratory Syndrome (SARS) virus."

The compound was demonstrated to be 100 percent effective in preventing influenza A in ferrets¹, in an earlier, separate study, also performed by Retroscreen Virology. Quigley announced the results of that study in November 2003.

Dr. Oxford, the chief study investigator stated that, "The widening of the antiviral spectrum of this compound to include the family of Corona viruses including SARS is a significant step forward. It is rather unusual to have a broad-spectrum antiviral drug. This gives the compound more practical potential."

Dr. Oxford continued, "My recommendation regarding the results of the initial invitro study and three subsequent Influenza animal model studies is that the company embarks upon a final animal model study to determine an exacting dose as would be appropriate for human subjects. Upon dosage determination, a human study can be designed using a virus challenge with Influenza A virus in a quarantine unit."

Dr. Oxford presented the preliminary SARS study results to Quigley's Scientific Advisory Board at a meeting held on Friday, December 5, 2003 in Philadelphia, Pennsylvania.

Retroscreen Virology Limited is an independent research virology company affiliated with the University of London. Professor John S. Oxford, the firm's senior scientist, is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. Dr. Oxford is the co-author of two standard texts on influenza and virology and has published more than 250 scientific papers throughout the world. Retroscreen specializes in developing anti-viral compounds and vaccines, and has worked with many pharmaceutical companies to assist them in developing products that now help to fight viral disease worldwide. Additional information is available on the company's website at www.retroscreen.com.

Dr. Richard Rosenbloom, Executive Vice President and Chief Operations Officer of Quigley Pharma Inc., stated, "Based on these preliminary in vitro results with SARS, we plan to pursue submission to the appropriate governmental bodies for immediate review and determination of next steps."

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGGTM) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGGTM) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the Influenza Formula Test Compound to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.